FDA releases draft guidance on medical device cybersecurity

Agency’s recommendations for manufacturers will better protect their products against threats, says Commissioner Scott Gottlieb.

Save
Share

    The Food and Drug Administration has released draft guidance to the healthcare industry identifying issues related to cybersecurity that manufacturers should address in the design and development of medical devices.

    The FDA’s document, which recommends that these considerations be included in premarket submissions for devices with cybersecurity risks, builds on the framework that the FDA created in its 2014 guidance for manufacturers.

    “These recommendations can facilitate an efficient premarket review process and help ensure that marketed medical devices are sufficiently resilient to cybersecurity threats,” states the guidance.

    FDA Commissioner Scott Gottlieb said in a written statement that the “draft premarket cybersecurity guidance provides updated recommendations for device manufacturers on how they can better protect their products against different types of cybersecurity risks, from ransomware to a catastrophic attack on a health system.”

    In addition, Gottlieb noted that “because of the rapidly evolving nature of cyber threats, we’re updating our guidance to make sure it reflects the current threat landscape so that manufacturers can be in the best position to proactively address cybersecurity concerns when they are designing and developing their devices.”

    Also See: FDA issues ‘playbook’ to providers for medical device cybersecurity

    According to the FDA, the guidance includes new recommendations such as a “cybersecurity bill of materials,” which lists the commercial software and hardware device components that may have vulnerabilities.

    “Depending on the level of cybersecurity risk associated with a device, this list can be an important resource to help ensure that device users are able to respond quickly to potential threats,” states the agency. “The draft guidance also introduces two tiers of devices—those with higher cybersecurity risk, including implanted devices such as pacemakers or neurostimulation devices, and standard cybersecurity risk, which includes devices that contain software—based on potential harm to patients from cybersecurity threats.”

    The FDA will hold a public workshop on January 29 and 30 to discuss the draft guidance.